BORTEZOMIB
Generic: BORTEZOMIB
BluePoint LaboratoriesManufacturer
INTRAVENOUS, SUBCUTANEOUSRoute
BORTEZOMIBActive Substance
2022-07-26Original Approval
BORTEZOMIB is FDA application ANDA209622, sponsored by MSN. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
PLASMA CELL MYELOMA
5,249 reports
2
OFF LABEL USE
3,253 reports
3
DRUG INEFFECTIVE
2,307 reports
4
NEUROPATHY PERIPHERAL
1,904 reports
5
THROMBOCYTOPENIA
1,807 reports
6
DEATH
1,591 reports
7
PNEUMONIA
1,575 reports
8
NEUTROPENIA
1,428 reports
9
DIARRHOEA
1,414 reports
10
FATIGUE
1,162 reports